We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FRD:NASDAQFriedman Industries Inc. Analysis

Data as of 2026-04-04 - not real-time

$17.25

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

FRD is trading at $17.25, which sits below its 20‑day (≈$17.61), 50‑day (≈$18.64) and 200‑day (≈$19.11) simple moving averages, signaling a bearish price bias. The 14‑day RSI of ~39.9 places the stock in the lower‑half of its range, hinting at potential oversold conditions but not yet in extreme territory. A modestly positive MACD histogram (+0.036) and a MACD line that has just crossed above its signal line provide a faint bullish cue amid the overall downtrend. Volume has been on a decreasing trajectory, and the 30‑day volatility of roughly 30% underscores a relatively choppy trading environment. Despite a low beta of ~0.52, the combination of bearish trend direction and weakening liquidity suggests short‑term caution.
Fundamentally, FRD appears cheap with a trailing PE of ~7.8 and a price‑to‑book below 1, yet its margins are thin (gross ≈12.6%, operating ≈2.3%) and cash conversion is negative, reflected in a –$51 M free‑cash‑flow figure. The balance sheet is leveraged, with debt exceeding $97 M and a debt‑to‑equity ratio near 68%, though the dividend payout ratio is only about 7%, making the current 0.93% yield appear sustainable. Recent corporate actions—a modest $0.04 per share dividend declaration, a CEO share purchase, and an announced expansion of the Sinton, Texas facility—provide a modest growth catalyst. In this context, the stock’s valuation leans toward being undervalued, but the high debt load and cash‑flow weakness temper optimism. Investors should weigh the cheapness against the liquidity and leverage concerns when forming a view.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price below key moving averages
  • decreasing volume trend
  • close to support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • robust revenue growth
  • facility expansion in Texas
  • valuation multiples below market averages

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • opportunity to improve cash generation
  • stable beta and sector exposure
  • dividend sustainability with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth78.60%
Profit Margin2.68%
P/E Ratio7.8
ROE11.62%
ROA4.69%
Debt/Equity68.30
P/B Ratio0.9
Op. Cash Flow$-658000
Free Cash Flow$-51404812

Technical Analysis

TrendBearish
RSI39.9
Support$16.55
Resistance$18.73
MA 20$17.61
MA 50$18.64
MA 200$19.11
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

GradeUndervalued
TypeBlend
Dividend Yield0.93%

Risk Assessment

Beta0.52
Volatility29.90%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.